Serum prolactin concentrations were measured using a sensitive bioassay (Nb2 assay) and by radioimmunoassay in II patients with prolactin-secreting pituitary tumours (median serum immunoactive prolactin 5150 mUlL), and in 58 normal control subjects (median prolactin 190mU/L). The mean ratio of serum prolactin bioactivity to immunoactivity was significantly lower in patients with prolactinornas than in normoprolactinaemic controls. Ten lactating women in the early post-partum period (median prolactin 3800mU/L), studied as a model of physiological hyperprolactinaemia, also had reduced bioactivity to immunoactivity ratios. Overall, there was a significant negative correlation between bioactivity: immunoactivity ratio and serum immunoactive prolactin.
Interest in prolactin (hPRL) bioactivity has arisen because of the discrepancies sometimes apparent between serum hPRL immunoactivity (hPRL-RIA) and clinical signs and symptoms, and because of the marked molecular heterogeneity of circulating hPRL. Serum hPRL consists of a number of modified forms in addition to monomeric hPRL. 1 A post-translationally modified glycosylated monomeric form (g-PRL)/ covalently-bonded oligomers, and aggregates are of particular interest because there is evidence that they may have widely different activities in different assays."? The development of the highly sensitive Nb2 rat lymphoma cell bioassay (BA) for lactogens," and its modification to allow the accurate measurement of serum prolactin bioactivity (hPRL-BA) alone," have allowed the study of bioactivity to immunoactivity (B:I) ratios of hPRL in serum samples from patients with a wide range of conditions. We have used the Nb2 bioassay and radioimmunoassay (RIA) to study serum samples from patients with hPRL-secreting pituitary tumours and women with physiological hyperprolactinaemia. We sought to determine Correspondence: Dr C R Smith, Department of Rheumatology, The Whittington Hospital, Highgate Hill, London NI9, UK. whether there are significant changes in the relative bioactivity of hPRL in these samples when compared with those from normoprolactinaemic control subjects, in which we and others have found bioactivity to immunoactivity ratios of close to unity.9,10
PATIENTS AND METHODS

Patients
Details of the II patients (9 women, 2 men) with pituitary prolactinomas are shown in Table I . Their mean age was 33·6 years (19-56 years). Two patients were taking bromocriptine at the time of this study.
Lactating women Ten women who were breast-feeding were studied. Their mean age was 29·6 years, range 20-38 years. Blood was collected between the fifth and seventh post-partum day, a time when serum prolactin levels are consistently elevated.
Normoprolactinaemic control subjects A group of 58 healthy control subjects was studied. There were 36 men and 22 women. Apart from three women taking either the oral contraceptive pill or hormone replacement, control subjects were taking no medication. Their mean age was 42·5 years, range 18-70 years.
Blood was taken from all subjects at least 3 h after waking, serum was separated after centrifugation and stored at -20°C until assay.
Methods
Radioimmunoassay
Reagents were obtained from NETRIA (St Bartholomew's Hospital, London, UK). The standard used was calibrated against International Standard 83/562 (National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK). Between-batch coefficients of variation (CV) were 10% at 130mU/L, 6·7% at 540mU/L and 5·8% at 1150mU/L.
Nb2 bioasssay
The assay was performed exactly as described previously." All serum samples were diluted at least I :40 in assay medium and assayed in duplicate at two or more dilutions (three or four for most serum samples with levels above 5000 mUlL) and the mean of these results calculated. Mitogenic activity due to growth hormone was routinely blocked with a monoclonal antibody to human growth hormone." A standard curve was prepared for each assay. The standard used was International Standard 83/562 (National Institute for Biologi-cal Standards and Control, Potters Bar, Hertfordshire, UK). Between-batch CV was < 12% over the range 120-1000mU/L (after dilution) and within-batch CV (calculated from the difference between duplicates of samples in the assay) was < 8% over the range 120-15000 mU /L. The detection limit for hPRL was 25mU/L.
Statistical methods
Serum concentrations of hPRL bioactivity and immunoactivity were not normally distributed so the median, range and interquartile range are used to describe these data. Bioactivity:immunoactivity ratios approximated to a normal distribution. Non-parametric methods (Mann-Whitney U test) or unpaired t-tests were used as appropriate to compare the distributions, and linear regression analysis of logarithmically-transformed results used to assess correlations.
Results
Serum samples from both normal subjects and patients were found to give results parallel with the standard curves in the bioassay. We found no evidence of bioassay activity attributable to placental lactogen in serum from lactating women (studied 5-7 days post-partum). In view of this, and evidence that placental lactogen disappears from the maternal circulation with a half-time of only 20 min after delivery of the 
"P < 0-001, tP < 0'005 compared with normal subjects.
placenta,I 1 radioimmunoassay for placental lactogen was not performed. hPRL levels and hPRL B:I ratios in female control subjects taking oestrogens were not different from those in the other women studied.
Reference ranges for hPRL bioactivity in serum and for the ratio of bioactivity to immunoactivity were established. The absolute range of hPRL bioactivity values in the 58 normal subjects was 65-568 mUjL (median 200mUjL, interquartile range 131-280 mUjL). The range of immunoactivity values was 70-570 mUjL in normal subjects, with a median of 190mUjL and an interquartile range of 12D-260mUjL. Bioactive hPRL was generally higher than immunoactive hPRL in normal subjects (mean B:I ratio 1·11, SEM 0·03 ( Table   2 ».
Serum hPRL was considerably elevated both in patients with prolactinomas and in lactating women ( Table 2 ). Bioactive hPRL was lower than immunoactive hPRL in both groups, and the B:l ratios were significantly lower than in normal subjects (prolactinomas vs controls P < 0'001; lactating women vs controls P < 0,005, Table 2 ). Figure I shows the relationship between B:l ratio and serum hPRL measured by RIA for all the subjects studied. There was a significant inverse correlation (r = -0·52, P < 0'001), with the highest B:l ratios in normal subjects. Figure 2 shows the relationship between Nb2 bioassay and RIA estimates of serum hPRL. The correlation overall was close, with good agreement between the two assays at most levels of serum hPRL (r = 0'97, P < 0·001 for all observations together).
DISCUSSION
It is now well-established that the pituitary glycoprotein hormones exist in variant forms with widely different biological activities. In the case of the gonadotrophins (FSH and LH) changes in the structure of the hormone may even result in the production of competitive antagonists to the active hormone, and variant forms of the hormones are believed to be of considerable physiological importance. 12 Changes in the bioactivity to immunoactivity ratio of TSH have also been described in a few cases. These changes in bioactivity are believed to be due to alterations in the structure of the carbohydrate portion of the molecule. Possible analogous variant forms of the pituitary peptide hPRL have until recently received little attention, partly because the hormone was not believed to be glycosylated. In this paper we describe a change in the ratio of bioactive to immunoactive hPRL in patients with hyperprolactinaemia, and discuss possible reasons for this.
Several studiesJ·IJ.14 have provided evidence that the proportion of larger forms of hPRL may be increased in the serum of patients with prolactinomas, possibly as a result of secretion by the tumour. However other workers 1 s-17 have found no difference in the proportion of high molecular weight forms between patients with prolactinomas and normal subjects.
An additional source of heterogeneity of hPRL, glycosylation, has been described recently.2A carbohydrate side-chain is attached, probably at position 31 in the hPRL chain, increasing the apparent molecular weight to 25 KDa. In serum samples from normoprolactinaemic individuals studied by immunoprecipitation and immunoblotting, glycosylated hPRL is the predominant form.": 19 The proportion of hPRL which is glycosylated is markedly reduced in patients with prolactinomas" and in lactating women (I Hashim, unpublished observations), and others" have found a similar reduction in women entering spontaneous labour.
In the absence of purified standards for each form it is as yet impossible to determine absolute values in terms of mass, and so studies must rely on ratios of activity in one assay to that in the other. Clearly even large changes in activity, if similar in the two assays, may yet result in an unchanged ratio, and ratios ofimmunoactivity to Nb2 assayable activity will vary with the immunoassay used as well as the bioactivity of the hormone.
Most authors report that the 'big' (40-60KDa) and 'big big' (> 100KDa) forms are of reduced activity in radio-receptor assays':" and the Nb2 assay' compared with monomeric (23 KDa) hPRL, although the lack of suitable standards makes comparisons difficult. The affinities of the larger forms of hPRL for antibodies used in RIAs have been compared with those of monomeric hPRL, and again results are conflicting.i'v" with significant differences reported by some authors.
Some data are available on the effect of glycosylation on hPRL activity in bioassays and immunoassays. It is clear that glycosylation reduces activity in the Nb2 assay by about twothirds when compared with non-glycosylated hPRL 6. 7 and relative activity is also considerably reduced in some immunoassays.i' There have been several previous studies of hPRL bioactivity in patients with hyperprolactinaemia and pituitary tumours, but these have studied small numbers of patients and given conflicting results. Subramanian et al. 2J studied 14 patients with hyperprolactinaemia of unspecified cause and 12 normoprolactinaemic control subjects. They, like us, found that while bioassay and radioimmunoassay results were very similar in control subjects, bioassay results were lower than immunoassay results in hyperprolactinaemic patients. Other investigators, however, have found excellent agreement between bioassay and immunoassay results in patients with pro lactinomas lO • 24 and in women in late pregnancy." These conflicting findings might be explained by the use of different immunoassays, or by differences in bioassay techniques.
The bioassay methods used in all these studies have been similar, with differences relating mainly to the dilutions at which samples of normal serum are assayed and to the use of various anti-GH and anti-PRL antisera. We have taken particular care over dilution of normal serum samples because of the finding that nonlactogenic serum factors may give falsely raised hPRL bioactivity results unless serum samples are adequately diluted in the assay.9. 26 We have also used a monoclonal antibody rather than antiserum to block hGH activity in the assay to overcome the problem of cross-reactivity of anti-hGH antisera with hPRL. Our method allows the detection of any other mitogenic factors, such as placental lactogens, present in serum. On theoretical grounds, 11 we did not expect to find any placental hormone activity still present in serum samples from women more than 5 days post-partum, and we did not in fact find any.
Clearly it is important to consider the possibility that the lower bioactivity results obtained in this study in samples from patients with high hPRL levels merely reflect the considerable dilution required before bioassay. We believe that the parallelism observed when the serum samples were assayed at several dilutions makes this explanation very unlikely.
Glycosylated hPRL has significantly altered activity in both the Nb2 bioassay and in some immunoassays; we do not have data on its activity in the NETR1A system which we used. However we believe that the change in B: I ratio which we observed is likely to relate to the reduction in the proportion of serum hPRL which is glycosylated in hyperprolactinaemic states. The most important question for clinical biochemists is whether alterations in hPRL B:1 ratios in different clinical states are clinically relevant. The finding of altered ratios in patients with physiological as well as tumour-related hyperprolactinaemia implies that this is not a phenomenon related specifically to production of abnormal hPRL by prolactinomas, and so could not be used as a diagnostic test. We found a good overall correlation between immunoassay and bioassay results, and it seems likely that immunoassays will continue to provide adequate information for most clinical uses.
